Menopause and metabolic syndrome: the five markers every woman should know

Metabolic syndrome is a cluster of five clinical markers that, when three or more appear together, sharply raise the risk of type 2 diabetes and cardiovascular disease. In the decade after menopause, the prevalence of metabolic syndrome roughly doubles — from about 20% of pre-menopausal women to close to 40% of postmenopausal women. The transition itself is the primary driver.

The five markers (NCEP ATP III criteria)

• Waist circumference greater than 35 inches (88 cm) in women
• Fasting triglycerides ≥ 150 mg/dL
• HDL cholesterol below 50 mg/dL in women
• Blood pressure ≥ 130/85 mmHg or on treatment
• Fasting glucose ≥ 100 mg/dL or on treatment

Three or more of these criteria constitute the diagnosis. Two of the five put a woman on a clear trajectory toward it if unaddressed.

Why menopause clusters these

Estradiol loss simultaneously affects fat distribution, insulin signaling, lipid metabolism, and vascular tone. So it is not coincidence that a woman who develops abdominal weight gain around menopause often also sees her triglycerides climb, her HDL drop, her blood pressure creep up, and her fasting glucose edge higher — all within a few years. The five markers are downstream effects of the same hormonal shift.

Why standard cholesterol testing is not enough

A traditional lipid panel misses a lot. ApoB (a direct count of atherogenic lipoprotein particles) and Lp(a) (a genetic risk marker) provide a much more accurate cardiovascular risk picture — and both often shift unfavorably in menopause. Any woman with two or more metabolic syndrome markers should have ApoB tested.

What reverses the cluster

A meta-analysis in the Annals of Internal Medicine found that hormone therapy started within the menopausal window reduces waist circumference, fasting insulin, LDL, and blood pressure — improving four of the five metabolic syndrome markers simultaneously. Resistance training and protein-forward nutrition amplify those effects. For women who meet clinical criteria, GLP-1 therapy addresses waist, glucose, triglycerides, and blood pressure together. The point is that metabolic syndrome does not require five different interventions — it requires one coherent, hormonally-informed protocol.

When to escalate

Women with three or more metabolic syndrome markers, a family history of premature cardiovascular disease, or an elevated ApoB should be evaluated for pharmacologic support alongside lifestyle intervention. Our [metabolic health service](/service/metabolic-health) integrates hormone, cardiometabolic, and GLP-1 evaluation in one clinical protocol.

The bottom line

Metabolic syndrome is not inevitable after menopause — but it is common enough that every woman should know her five numbers by 50. The earlier the cluster is caught, the more reversible it is.

Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026